Boustead/Biotreat

Boustead has struck a deal to buy $42.7m worth of 1% 5-year redeemable convertible notes, which can be converted into 854.2m Biotreat shares representing 20.4% stake in the China-based water treatment company. Boustead views the acqn as complementary and synergistic to its water and wastewater business given Biotreat’s extensive portfolio of BOT and TOT wastewater projects in China with a potential treatment capacity of over 1m tpd.